CORCEPT THERAPEUTICS INC Deferred Income Tax Expense (Benefit)
CORCEPT THERAPEUTICS INC (CORT) reported Deferred Income Tax Expense (Benefit) of -$10.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $2.88M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$13.11M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$15.18M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $9.11M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for fiscal 2025 was -$37.54M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for fiscal 2024 was -$40.19M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for fiscal 2023 was -$29.49M.
- CORCEPT THERAPEUTICS INC deferred income tax expense (benefit) for fiscal 2022 was -$33.91M, a 880.14% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$10.23M 10-Q · filed 2026-07-29 | -$25.41M derived: sum of 3 quarters · filed 2026-07-29 | -$16.30M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | -$13.11M 10-Q · filed 2026-04-30 | -$28.29M derived: sum of 2 quarters · filed 2026-04-30 | -$19.18M derived: sum of 3 quarters · filed 2026-04-30 | -$36.94M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | -$15.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$6.07M derived: sum of 2 quarters · filed 2026-02-24 | -$23.83M derived: sum of 3 quarters · filed 2026-07-29 | -$37.54M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $9.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$8.65M derived: sum of 2 quarters · filed 2026-07-29 | -$22.36M 10-Q · filed 2025-11-04 | -$26.21M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | -$17.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$31.47M 10-Q · filed 2026-07-29 | -$35.33M derived: sum of 3 quarters · filed 2026-07-29 | -$50.53M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | -$13.71M 10-Q · filed 2026-04-30 | -$17.56M derived: sum of 2 quarters · filed 2026-04-30 | -$32.77M derived: sum of 3 quarters · filed 2026-04-30 | -$46.73M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$19.07M derived: sum of 2 quarters · filed 2026-02-24 | -$33.03M derived: sum of 3 quarters · filed 2026-02-24 | -$40.19M 10-K · filed 2026-02-24 | |
| 2024-09-30 | -$15.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$29.17M derived: sum of 2 quarters · filed 2025-11-04 | -$36.33M 10-Q · filed 2025-11-04 | -$40.01M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | -$13.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$21.13M 10-Q · filed 2025-07-31 | -$24.80M derived: sum of 3 quarters · filed 2026-02-24 | -$33.66M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | -$7.16M 10-Q · filed 2025-05-05 | -$10.83M derived: sum of 2 quarters · filed 2026-02-24 | -$19.69M derived: sum of 3 quarters · filed 2026-02-24 | -$29.93M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$12.53M derived: sum of 2 quarters · filed 2026-02-24 | -$22.77M derived: sum of 3 quarters · filed 2026-02-24 | -$29.49M 10-K · filed 2026-02-24 | |
| 2023-09-30 | -$8.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$19.09M derived: sum of 2 quarters · filed 2024-10-30 | -$25.82M 10-Q · filed 2024-10-30 | -$30.29M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | -$10.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-29 | -$16.96M 10-Q · filed 2024-07-29 | -$21.43M derived: sum of 3 quarters · filed 2025-02-26 | -$30.30M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | -$6.73M 10-Q · filed 2024-05-01 | -$11.19M derived: sum of 2 quarters · filed 2025-02-26 | -$20.07M derived: sum of 3 quarters · filed 2025-02-26 | -$30.70M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | -$4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$13.34M derived: sum of 2 quarters · filed 2025-02-26 | -$23.97M derived: sum of 3 quarters · filed 2025-02-26 | -$33.91M 10-K · filed 2025-02-26 | |
| 2022-09-30 | -$8.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$19.50M derived: sum of 2 quarters · filed 2023-11-01 | -$29.44M 10-Q · filed 2023-11-01 | -$27.14M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | -$10.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$20.57M 10-Q · filed 2023-08-02 | $404.00K 10-Q · filed 2022-08-04 | -$18.27M derived: sum of 3 quarters · filed 2024-02-15 | -$16.73M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$9.94M 10-Q · filed 2023-05-03 | -$7.64M derived: sum of 2 quarters · filed 2024-02-15 | -$6.10M derived: sum of 3 quarters · filed 2024-02-15 | -$229.00K derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $3.83M derived: sum of 2 quarters · filed 2024-02-15 | $9.71M derived: sum of 3 quarters · filed 2024-02-15 | $4.35M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.41M derived: sum of 2 quarters · filed 2022-11-03 | $2.05M 10-Q · filed 2022-11-03 | $4.36M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $514.00K 10-Q · filed 2022-08-04 | -$2.06M 10-Q · filed 2021-07-29 | $2.83M derived: sum of 3 quarters · filed 2023-02-28 | $4.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$5.36M 10-Q · filed 2022-05-05 | -$3.05M derived: sum of 2 quarters · filed 2023-02-28 | -$1.29M derived: sum of 3 quarters · filed 2023-02-28 | $3.63M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.07M derived: sum of 2 quarters · filed 2023-02-28 | $8.99M derived: sum of 3 quarters · filed 2023-02-28 | $14.09M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $6.68M derived: sum of 2 quarters · filed 2021-11-03 | $11.78M 10-Q · filed 2021-11-03 | $16.92M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | $4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $10.02M 10-Q · filed 2021-07-29 | $15.16M derived: sum of 3 quarters · filed 2022-02-15 | $21.06M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-03-31 | $5.09M 10-Q · filed 2021-05-06 | $10.24M derived: sum of 2 quarters · filed 2022-02-15 | $16.14M derived: sum of 3 quarters · filed 2022-02-15 | $21.05M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2019-12-31 | $5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $11.04M derived: sum of 2 quarters · filed 2022-02-15 | $15.95M derived: sum of 3 quarters · filed 2022-02-15 | $16.88M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $10.80M derived: sum of 2 quarters · filed 2020-11-03 | $11.73M 10-Q · filed 2020-11-03 | $15.20M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-06-30 | $4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $5.83M 10-Q · filed 2020-08-04 | $9.30M derived: sum of 3 quarters · filed 2021-02-23 | $14.26M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2019-03-31 | $926.00K 10-Q · filed 2020-05-04 | $4.39M derived: sum of 2 quarters · filed 2021-02-23 | $9.35M derived: sum of 3 quarters · filed 2021-02-23 | $11.82M derived: sum of 4 quarters · filed 2021-02-23 | |
| 2018-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $8.43M derived: sum of 2 quarters · filed 2021-02-23 | $10.90M derived: sum of 3 quarters · filed 2021-02-23 | $14.07M 10-K · filed 2021-02-23 | |
| 2018-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $7.43M derived: sum of 2 quarters · filed 2019-11-07 | $10.60M 10-Q · filed 2019-11-07 | -$66.10M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $5.64M 10-Q · filed 2019-08-01 | -$71.06M derived: sum of 3 quarters · filed 2020-02-24 | -$71.06M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-03-31 | $3.17M 10-Q · filed 2019-05-09 | -$73.53M derived: sum of 2 quarters · filed 2020-02-24 | -$73.53M derived: sum of 3 quarters · filed 2020-02-24 | -$73.53M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2017-12-31 | -$76.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$76.70M derived: sum of 2 quarters · filed 2020-02-24 | -$76.70M derived: sum of 3 quarters · filed 2020-02-24 | -$76.70M 10-K · filed 2020-02-24 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $0.00 derived: sum of 2 quarters · filed 2018-11-02 | $0.00 10-Q · filed 2018-11-02 | ||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-09 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |